<DOC>
	<DOCNO>NCT01454505</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose AL-53817 ( Stage A ) evaluate safety efficacy AL-53817 treatment allergic rhinitis ( Stage B ) .</brief_summary>
	<brief_title>Safety Efficacy AL-53817 Nasal Spray Solution</brief_title>
	<detailed_description>Stage A 1-day , single ascend dose study utilize 7 separate cohort unique subject ( healthy normal volunteer ) . Each cohort administer different dose AL-53817 Nasal Spray Solution order determine maximum tolerate dose ( MTD ) . In Stage B , 2 different cohort unique , ragweed-sensitive subject administer MTD 5 day twice day determine safety efficacy AL-53817 Nasal Spray Solution treatment allergic rhinitis . Subjects require meet minimum allergic rhinitis score two qualify EEC visit participate study . Subjects continually house clinic 5-day treatment period .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Stage A Willing able give write informed consent . In good health opinion appropriately qualified physician . Females childbearing potential ( least 1 year postmenopausal surgically sterilize ) must negative urine pregnancy test Visit 1 , must nurse plan become pregnant course study . Other protocoldefined inclusion criterion may apply . Stage B History nonrecalcitrant seasonal allergic rhinitis fall allergy season . Allergy short ragweed allergen , define positive skin prick test short ragweed allergen within 12 month prior Visit 1 . Be good health opinion appropriately qualified physician . Females childbearing potential ( least 1 year postmenopausal surgically sterilize ) must negative urine pregnancy test Visit 1 , must nurse plan become pregnant course study . Other protocoldefined inclusion criterion may apply . Stage A Hypersensitivity study drug component test article , include benzalkonium chloride . Using prescription nonprescription systemic topical medication , vitamin dietary supplement within 14 day prior checkin day ( except acetaminophen dos &lt; 2 grams/day topical , hormonaloral , implantable injectable contraceptive ) . Current recent history severe , unstable , uncontrolled condition base upon review medical history and/or physical examination . Any nasal disorder could preclude safe administration study medication and/or interfere evaluation study medication . History HIV , hepatitis B active hepatitis A determine medical history and/or serology Screening Visit . Any screen clinical laboratory result ( hematology , serum chemistry urinalysis ) outside normal range clinically relevant opinion appropriately qualified physician and/or Alcon physician . Participation investigational study within 30 day entry study concomitantly study . Other protocoldefined exclusion criterion may apply . Stage B Any screen clinical laboratory result ( hematology , serum chemistry urinalysis ) outside normal range clinically relevant opinion appropriately qualified physician and/or Alcon physician . Using prescription nonprescription systemic topical medication , vitamin dietary supplement within 14 day prior checkin day ( except acetaminophen dos &lt; 2 grams/day topical , hormonaloral , implantable injectable contraceptive ) . History HIV , hepatitis B C active hepatitis A determine medical history and/or serology Screening Visit . Any nasal disorder could preclude safe administration study medication and/or interfere evaluation study medication . Confirmed diagnosis chronic rhinosinusitis within 12 month Visit . Confirmed diagnosis severe rhinitis rhinosinusitis prior Visit 1 , opinion Investigator , would preclude safe subject participation study . Current recent history severe , unstable , uncontrolled condition , opinion Investigator , would preclude safe participation study . Participation investigational study within 30 day entry study concomitantly study . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Healthy subject</keyword>
	<keyword>Nasal allergy</keyword>
	<keyword>Allergies</keyword>
	<keyword>Environmental Exposure Chamber</keyword>
	<keyword>EEC</keyword>
	<keyword>Ragweed</keyword>
</DOC>